Planeeria For Profit
Planeeria focuses on developing a product based on recombinant human amelogenin as an active ingredient for the treatment of injured cartilage and ligaments. The company develops innovative products for regeneration and recovery after injuries. Planeeria was founded in 2018 and is headquartered in
Founded Date:
01.05.2018
Last Funding Type:
N/A
Headquarters:
Lod, HaMerkaz, Israel
Technology:
Tissue engineering
Employee Number:
N/A
Industry:
Regenerative Medicine
Estimated Revenue:
$0
Last Funding Date:
N/A
Funding Status:
N/A
Total Funding:
$0